pyrroles has been researched along with s 1033 in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (28.95) | 29.6817 |
| 2010's | 26 (68.42) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, C | 1 |
| Fletcher, JA; Rubin, BP | 1 |
| von Mehren, M | 1 |
| Thomas, X | 1 |
| Bui, B; Italiano, A | 1 |
| Kimura, S; Maekawa, T; Morinaga, K; Ueda, T; Yamauchi, T | 1 |
| Sevinc, A | 1 |
| Gelderblom, H; Grünwald, V; Hartmann, JT; Joensuu, H; Leyvraz, S; Montemurro, M; Reichardt, P; Roth, A; Schöffski, P; Schütte, J; Seddon, B; von Moos, R; Weber, E; Wendtner, CM | 1 |
| Eisterer, W; Ploner, F | 1 |
| Reichardt, P | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| Beck, MY; Chang, HM; Choi, DR; Kang, YK; Kim, KP; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Doi, T; Kakeji, Y; Kanda, T; Komatsu, Y; Nishida, T; Ohtsu, A; Onozawa, Y; Sawaki, A; Yamada, Y; Yamasaki, M | 1 |
| Lewis, VO; Ravi, V; Wang, WL | 1 |
| Geoerger, B; Leblond, P | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Bove, B; Cauchi, C; Davey, M; Engstrom, PF; Lee, J; Litwin, S; Lopez, M; Somaiah, N; von Mehren, M | 1 |
| Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S | 1 |
| George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
| Athanasou, NA; Bradley, KM; Dijkstra, PD; Gelderblom, H; Gibbons, CL; Hassan, AB; Hogendoorn, PC; Kroep, JR; Nout, RA; van de Sande, MA; van der Heijden, L; van Rijswijk, CS | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| Ding, JF; Zhong, DF | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z | 1 |
| Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
| Bagan, P; Bilan, P; Couffinhal, JC; Dakhil, B; Fargeas, C; Mahé, E; Roger, A; Sigal, ML; Sin, C | 1 |
| Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
16 review(s) available for pyrroles and s 1033
| Article | Year |
|---|---|
KIT mutations in GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Models, Biological; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sunitinib | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
[Treatment of extensive disease].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Long-Term Care; Neoplasm Invasiveness; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
[Internal medical therapy of gastrointestinal stroma tumors].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Topics: Antineoplastic Agents; Benzamides; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Macrophage Colony-Stimulating Factor; Macrophages; Piperazines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Soft Tissue Neoplasms; Sunitinib; Synovial Membrane; Synovitis, Pigmented Villonodular; Tendons | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
Topics: Adult; Antineoplastic Agents; Arthroplasty; Arthroscopy; Benzamides; Chemotherapy, Adjuvant; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radioisotopes; Radiotherapy, Adjuvant; Sunitinib; Synovectomy; Synovial Membrane; Tendons; Tenosynovitis | 2013 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2014 |
3 trial(s) available for pyrroles and s 1033
| Article | Year |
|---|---|
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Topics: Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
19 other study(ies) available for pyrroles and s 1033
| Article | Year |
|---|---|
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases | 2008 |
Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Patient Selection; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Tyrosine kinase inhibitors and acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pancreatitis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biological Availability; Compassionate Use Trials; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Half-Life; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)].
Topics: Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Humans; Indoles; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Pyrroles; Sunitinib; Withholding Treatment; Wound Healing | 2017 |
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |